Loading
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Previous close
$5.37
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Day range
Current $5.37
52-week range
Current $5.37
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
50
Mixed
Risk
32
Moderate Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Day range
Current $5.37
52-week range
Current $5.37
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 245K USD | 78.03M USD | 44.26M USD | 27.88M USD | 28.99M USD |
| Gross profit | −245K USD | −78.03M USD | −44.26M USD | −27.88M USD | −28.99M USD |
| Research and development | 81.4M USD | 78.03M USD | 44.26M USD | 27.88M USD | 28.99M USD |
| Selling, general, and administrative | 42.06M USD | 25.04M USD | 15.67M USD | 10.93M USD | 12.35M USD |
| Operating expenses | 123.3M USD | 25.17M USD | 15.75M USD | 10.96M USD | 12.49M USD |
| Interest income | 4.16M USD | 6.47M USD | 4.44M USD | 88 USD | 2.28K USD |
| Interest expense | — | — | — | 88K USD | 2.28M USD |
| Depreciation and amortization | 245K USD | 130K USD | 77K USD | 31K USD | 136K USD |
| Operating income | −123.55M USD | −103.2M USD | −60.01M USD | −38.84M USD | −41.48M USD |
| Net income | −118.84M USD | −95.88M USD | −54.7M USD | −38.15M USD | −43.01M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI33.66M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM21.16M0.03%79.88B USD0.19%$296.01+0.28%
State Street SPDR S&P Biotech ETFXBI18.3M0.16%11.49B USD0.35%$163.81-0.35%
Vanguard Extended Market ETFVXF8.58M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO7.68M0.05%14.58B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO4.69M0.03%17.4B USD0.06%$119.62+0.25%
iShares Biotechnology ETFIBB4.28M0.04%10.72B USD0.44%$211.92-0.88%
F/M Emerald Life Sciences Innovation ETFLFSC3.67M2.90%126M USD0.79%$46.1341-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBF/M Emerald Life Sciences Innovation ETFLFSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
